

Serial No. 08/913,555

Claim 58, line 2, change "1" to --57-- and delete "exhibits higher";

line 3, change "inhibitory activity against" to --inhibits--; and

line 4, delete "(effective concentration)" and after "ml" insert --more--.

Claim 59, line 3, after "antibody" insert --or fragment thereof-- and change "Fas-expressed" to --Fas expressing--.

Claim 60, line 2, change "3" to --59--; and

line 3, delete "(i.e., apoptosis inhibition rate)";

Claim 62, line 2, change "5" to --61--.

Claim 63, line 2, change "5" to --61--.

Claim 64, line 3, change "5" to --61--.

Claim 65, line 1, change "8" to --64--.

Claim 66, line 1, change "9" to --65--.

Claim 67, line 3, change "5" to --61--.

Claim 68, line 1, change "11" to --67--.

Claim 79, line 4, delete "(excluding the human)";

line 6, change "ligand-expressed" to --ligand expressing--;

Serial No. 08/913,555

line ~~11~~<sup>5</sup>, change "which" to --that--;

line 12, change "to culture" to --so that--; and

line 13, after "cells" insert --are cultured--.

Claim 80, line 2, change "23" to --79--.

Claim 81, line 2, change "23" to --79--.

Claim 160, line 1, change "monoconal" to --monoclonal--;

lines 3-4, delete "(excluding the human)";

line 6, change "expressed" to --expressing--;

line 11, change "which" to --that-- and change "to culture" to --so that--;

line 12, after "cells" insert --are cultured--;

line 18, change "expressed" to --expressing--; and

line 19, change "expressed" to --expressing--.

#### REMARKS

Further and favorable consideration is requested.

The claims have been renumbered to correspond with cancellation of claims 1-56 as directed in the Preliminary Amendment filed September 19, 1997. Accordingly, the claims are now renumbered as claims 57-160. This numbering scheme differs from that employed in the Action.

The application was indicated as failing to comply with the